Links:
Archives:
Newsletter:
Categories:
Using Facebook to Raise Parkinson’s Disease Awareness
Filed under General – November 14th, 2010
I recently read Focus on Cure’s most recent Facebook message and so I want to pass this on so that everyone who has a Facebook account can get involved, let me know if you have any questions.
As many of you know, Breast Cancer awareness has been popular the past few weeks, with placing of colors and numbers, and other fun ways on people’s status on Facebook. It even made it to the CNN news!!! Many of us want the same awareness for Parkinson’s Disease and Alzheimer’s Disease there for we thought of adding something different to our status for the next few days. For example, Day 1 (Wednesday 13th): round off number of people we know that have PD/Alzheimer’s (1-100), for those who ask what it means, say Stay tuned! Day 2 (Thursday 14th): (put family, friend, or self), meaning for those who has the illness, for those who ask again, say, Stay still tuned for the results!!! Day 3 (Friday 15th), final day: Everyone lists A symptom, such as (tremble, shake, memory), anything that pertains to the illness, then that evening you can post on your status the final result so they all know what you were referring to: Ex.. at the end comment: 100; Family; loss of thought process adding Parkinson’s Disease or Alzheimer’s Disease! Let’s get this awareness going!!! Thank you for your support!!!!
Parkinsons and CASS Certification
Filed under General – September 28th, 2010
The USPS uses CASS certification to correct and standardize address data, remove duplicate records, and validate the client’s mailing list information. It does this by checking the mailer’s zip and zip-plus-four codes and also delivery point codes, and it does it online in real time, so that ‘up-to-the-minute accuracy’ is exactly that. Scrubbing mailing lists regularly – every three months – is a requirement of the US Postal Service; more than that, it is a lifesaver.
A look at the average address database has shown that from 10 to 30% of addresses on a given database may be flawed if mailing to parkinsons sufferers. If you are the businessman who uses that database, you’ve just lost bunches of money, both from customers who aren’t going to see your mailing and from money spent attempting to locate those parkinsons and send them a second mailing. Most profit margins melt away under such circumstances. You want your mailing costs – postage, shipping, and handling – to go down and your profit margin from successful marketing campaigns to go up; so it only makes sense to embrace strategies that help that happen.
Ritalin: Reducing the Fear of Falling
Filed under Drugs, General, Health Care – July 29th, 2010
Getting old isn’t just about the body aches and pains. As we get older, our risk of falling greatly increases. Old bones don’t heal like young ones, and for those that are older falling can lead to death.
But researchers at Tel Aviv University provide hopeful news from an unexpected source. Ritalin, used for managing Attention Deficit Disorder in hyperactive children, may have therapeutic benefits for seniors too. Older people who take methylphenidate (the generic name for Ritalin) may improve their cognitive abilities and their gait, cutting the risk for serious falls. This surprising finding was made by Prof. Jeffrey M. Hausdorff, a lecturer at the Sackler School of Medicine at Tel Aviv University, and his colleagues, and reported in the Journal of the American Geriatrics Society.
TAU’s researchers are the first to investigate the power of
Read the rest of this entry »
My Parkinson’s Disease is Live Again!
Filed under Uncategorized – January 13th, 2010
After a short hiatus, My Parkinson’s Information will now be updated on a few times a week. Despite that lack of updates over the last little while, our website has served as a powerful source to those seeking greater support, information, and answers to their zip code world. We feel luck that you’ve made us a part of your life one way or another and we look forward to sharing zip code database with your the latest information for Parkinson’s disease.
Mayo Clinic Develops Potential New Therapy To Stop The Progression Of Parkinson’s Disease
Filed under Articles, Clinical Trial, Drugs, News – November 19th, 2008
Mayo Clinic (http://www.mayoclinic.org) researchers have developed a method to reduce the production of alpha-synuclein in the brain. Alpha-synuclein is a protein that is believed to be central to the cause of Parkinson’s disease (http://www.mayoclinic.org/parkinsons- disease). All patients with Parkinson’s disease have abnormal accumulations of alpha- synuclein protein in the brain.
The new method involves the delivery of RNA interference compounds directly to selected areas of the brain via injection. The RNA interference compounds silence the gene that produces alpha-synuclein, according to the Mayo researchers. The study was published this month in Molecular Neurodegeneration.
Parkinson’s disease is a progressive disorder that affects nerve cells in the part of the brain that controls muscle movement. Symptoms include tremor, slowed movement and rigid muscles. At least 1 million people in the U.S. are believed to have Parkinson’s disease, and 2 percent of the population can expect to develop the disease during their lifetime.
“While our research has not yet been tested on humans, we expect that these findings will lead to an effective treatment for slowing or even halting the progression of Parkinson’s disease,” says Demetrius Maraganore, M.D. (http://www.mayoclinic.org/bio/10345655.html), a Mayo Clinic neurologist.
Sergey Brin and Parkinson’s Disease
Filed under Articles, General – September 19th, 2008
Google co-founder Sergey Brin launched a personal blog Thursday, on which he revealed he has a genetic code that has been linked to having increased chances for developing Parkinson’s disease.
In the blog, too.blogspot.com, Brin says his mother and great aunt both were diagnosed with the degenerative brain disorder. Through 23andme Inc., a genetic testing organization, both Brin and his mother found they carry the G2019S mutation, which accounts for a substantial proportion of familial Parkinson’s, he wrote.
“The exact implications of this are not entirely clear,” Brin wrote in the blog. “Nonetheless, it is clear that I have a markedly higher chance of developing Parkinson’s in my lifetime than the average person.”
Brin deduced that he has a 20 percent to 80 percent higher-than-average chance to develop the disease, depending on the study and measurements.
“This leaves me in a rather unique position. I know early in my life something I am substantially predisposed to. I now have the opportunity to adjust my life to reduce those odds (e.g., there is evidence that exercise may be protective against Parkinson’s),” he wrote. “I also have the opportunity to perform and support research into this disease long before it may affect me. And, regardless of my own health, it can help my family members as well as others.”
Brin said he will help support research into the disease.
“I feel fortunate to be in this position,” he wrote. “Until the fountain of youth is discovered, all of us will have some conditions in our old age only we don’t know what they will be. I have a better guess than almost anyone else for what ills may be mine —and I have decades to prepare for it.”
EMEA Releases Guidelines On Development Of Medicines For Parkinson’s Disease
Filed under Drugs, Research – September 8th, 2008
The European Medicines Agency (EMEA) has released two guidelines for companies developing medicines for the treatment of Alzheimer’s disease and other dementias, and for Parkinson’s disease, in the light of recent scientific progress in the understanding of these diseases and conditions.
Advances in clinical science, physiopathology and molecular biology have stimulated new interest in the development of more effective symptomatic or disease-modifying treatments, i.e. early treatments that may prevent the emergence or slow down the progression of disease. The guidelines were developed in response to the need of companies developing these new types of medicines for guidance on appropriate clinical-trial designs.
As life expectancy increases, neurodegenerative diseases and dementia will affect more and more people over the coming decades, and these guidelines are expected to help improve the availability of medicines to treat such diseases and conditions. The guidelines will come into effect on 1 February 2009.
Choose your State or Apply to get started on your Free Trial:
Choose by State
| Parkinson's Disease | Copyright © 2007-2012 My Parkinson’s Information